BIIB - Biogen Inc.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Show:
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
10,173,400
10,173,400
10,981,700
13,444,600
14,377,900
Cost of revenue
2,278,300
2,278,300
2,109,700
1,805,200
1,955,400
Gross profit
7,895,100
7,895,100
8,872,000
11,639,400
12,422,500
Operating expenses
Research development
2,231,100
2,231,100
2,501,200
3,990,900
2,280,600
Selling general and administrative
2,403,600
2,403,600
2,674,300
2,504,500
2,374,700
Total operating expenses
4,993,200
4,993,200
6,064,000
7,193,100
5,386,800
Operating income or loss
2,901,900
2,901,900
2,808,000
4,446,300
7,035,700
Interest expense
246,600
246,600
253,600
222,500
187,400
Total other income/expenses net
847,200
689,900
-1,062,800
601,200
90,200
Income before tax
3,591,800
3,591,800
1,745,200
5,047,500
7,125,900
Income tax expense
632,800
632,800
52,500
992,300
1,158,000
Income from continuing operations
2,961,600
2,961,600
1,727,600
4,060,500
5,888,500
Net income
3,046,900
3,046,900
1,556,100
4,000,600
5,888,500
Net income available to common shareholders
3,046,900
3,046,900
1,556,100
4,000,600
5,888,500
Basic EPS
-
20.96
10.44
24.86
31.47
Diluted EPS
-
20.87
10.40
24.80
31.42
Basic average shares
-
145,300
149,100
160,900
187,100
Diluted average shares
-
146,000
149,600
161,300
187,400
EBITDA
-
3,267,800
3,689,300
4,911,100
7,525,600